Although wildtype p53 is present in most CM and MM, chemotherapeutics targeting the p53 pathway such as cisplatin or carboplatin are barely successful suggesting abrogated functional integrity of the accumulated protein [25]. This evidence concerns the gene TP53 and Miyoshi myopathy.